Apellis Pharmaceuticals, Inc.

We are a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing new therapeutic compounds. Our approach targets diseases with high unmet needs by inhibiting the complement system, a key part of the immune system. We currently have two marketed drugs that target C3, a central protein in the complement cascade. SYFOVRE (pegcetacoplan injection) was approved by the U.S. Food and Drug Administration (FDA) in February 2023 for treating geographic atrophy (GA) secondary to age-related macular degeneration. We launched SYFOVRE in the United States in March 2023. For the years ended December 31, 2025 and 2024, we generated $586.9 million and $611.9 million, respectively, in U.S. net product revenue from SYFOVRE sales. We have exclusive, worldwide commercialization rights for SYFOVRE and received marketing approval in Australia in January 2025. Our second drug, EMPAVELI (pegcetacoplan), was approved by the FDA in May 2021 for paroxysmal nocturnal hemoglobinuria (PNH) and in July 2025 for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (primary IC-MPGN). We are also developing a next-generation therapy for GA, combining SYFOVRE with APL-3007, a small interfering RNA (siRNA). We initiated a Phase 2 multi-dose clinical trial for this combination in GA patients in June 2025. We have exclusive U.S. commercialization rights for EMPAVELI.